These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 18502982

  • 1. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
    Lü S, Yang J, Song X, Gong S, Zhou H, Guo L, Song N, Bao X, Chen P, Wang J.
    J Pharmacol Exp Ther; 2008 Aug; 326(2):423-31. PubMed ID: 18502982
    [Abstract] [Full Text] [Related]

  • 2. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.
    Lü S, Yang J, Chen Z, Gong S, Zhou H, Xu X, Wang J.
    Exp Hematol; 2009 Jul; 37(7):831-7. PubMed ID: 19426847
    [Abstract] [Full Text] [Related]

  • 3. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
    Lü S, Chen Z, Yang J, Chen L, Gong S, Zhou H, Guo L, Wang J.
    Exp Hematol; 2008 Oct; 36(10):1278-84. PubMed ID: 18562081
    [Abstract] [Full Text] [Related]

  • 4. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
    Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, Inagaki A, Kusumoto S, Ishida T, Komatsu H, Shiotsu Y, Ueda R.
    Leukemia; 2010 Aug; 24(8):1506-12. PubMed ID: 20555361
    [Abstract] [Full Text] [Related]

  • 5. [Comparison of protein expression profiles between bortezomib-resistant JurkatB cells with PSMB5 mutation and their parent cells].
    Lü SQ, Yang JM, Huang CM, Xu XQ, Zhou H, Song NX, Wang JM.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):869-73. PubMed ID: 21867604
    [Abstract] [Full Text] [Related]

  • 6. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
    Yang YM, Lee S, Nam CW, Ha JH, Jayaraman M, Dhanasekaran DN, Lee CH, Kwak MK, Kim SG.
    Carcinogenesis; 2010 Jul 21; 31(7):1230-7. PubMed ID: 20478922
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
    Hutter G, Rieken M, Pastore A, Weigert O, Zimmermann Y, Weinkauf M, Hiddemann W, Dreyling M.
    Ann Hematol; 2012 Jun 21; 91(6):847-56. PubMed ID: 22231280
    [Abstract] [Full Text] [Related]

  • 11. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
    de Wilt LH, Jansen G, Assaraf YG, van Meerloo J, Cloos J, Schimmer AD, Chan ET, Kirk CJ, Peters GJ, Kruyt FA.
    Biochem Pharmacol; 2012 Jan 15; 83(2):207-17. PubMed ID: 22027222
    [Abstract] [Full Text] [Related]

  • 12. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
    Franke NE, Niewerth D, Assaraf YG, van Meerloo J, Vojtekova K, van Zantwijk CH, Zweegman S, Chan ET, Kirk CJ, Geerke DP, Schimmer AD, Kaspers GJ, Jansen G, Cloos J.
    Leukemia; 2012 Apr 15; 26(4):757-68. PubMed ID: 21941364
    [Abstract] [Full Text] [Related]

  • 13. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
    Verbrugge SE, Assaraf YG, Dijkmans BA, Scheffer GL, Al M, den Uyl D, Oerlemans R, Chan ET, Kirk CJ, Peters GJ, van der Heijden JW, de Gruijl TD, Scheper RJ, Jansen G.
    J Pharmacol Exp Ther; 2012 Apr 15; 341(1):174-82. PubMed ID: 22235146
    [Abstract] [Full Text] [Related]

  • 14. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E, Alvarez-Fernández S, Maiso P, Martín-Sánchez J, Vidriales MB, Garayoa M, Ocio EM, Montero JC, Pandiella A, San Miguel JF.
    Haematologica; 2008 Jan 15; 93(1):57-66. PubMed ID: 18166786
    [Abstract] [Full Text] [Related]

  • 15. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades N.
    Invest Ophthalmol Vis Sci; 2007 Oct 15; 48(10):4706-19. PubMed ID: 17898295
    [Abstract] [Full Text] [Related]

  • 16. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
    Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G.
    Blood; 2008 Sep 15; 112(6):2489-99. PubMed ID: 18565852
    [Abstract] [Full Text] [Related]

  • 17. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
    Nakata W, Hayakawa Y, Nakagawa H, Sakamoto K, Kinoshita H, Takahashi R, Hirata Y, Maeda S, Koike K.
    Int J Oncol; 2011 Dec 15; 39(6):1529-36. PubMed ID: 21785822
    [Abstract] [Full Text] [Related]

  • 18. Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
    Chu S, Alexiadis M, Fuller PJ.
    Reprod Sci; 2009 Apr 15; 16(4):397-407. PubMed ID: 19087975
    [Abstract] [Full Text] [Related]

  • 19. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Pahler JC, Ruiz S, Niemer I, Calvert LR, Andreeff M, Keating M, Faderl S, McConkey DJ.
    Clin Cancer Res; 2003 Oct 01; 9(12):4570-7. PubMed ID: 14555532
    [Abstract] [Full Text] [Related]

  • 20. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.